
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is expected to experience continued growth in 2026, driven by increasing penetration in open ablation, minimally invasive ablation, and pain management products, as well as the adoption of its EnCompass clamp as a quality metric for cardiac surgery. Additionally, the recent launch of its cryoSPHERE MAX probe for pain management has received positive feedback, contributing to strong sales in this segment. With a strong balance sheet and a focus on innovation, AtriCure is well-positioned to compete with potential competitors, such as Edwards Lifesciences.
Bears say
AtriCure is facing threats to sales from new competitors, such as Edwards Lifesciences, launching their own surgical left atrial appendage closure device later this year and possibly causing market share loss and slower margin improvement. In addition, there is a risk of weaker sales and slower earnings growth due to potential unmet patient needs. Furthermore, AtriCure may see slower free cash flow if sales are not meeting expectations.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares